User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring
User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring
批准号:
10459077
负责人:
Keiichiro Kushiro
金额:
$25.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-01 至 2024-08-31
关键词:
AddressAdherenceAdoptionAntibodiesAntigen TargetingAntigensAppearanceBehaviorBehavioralBenefits and RisksBindingBiomanufacturingCharacteristicsClinicClinical TrialsCoitusColorComplexContraceptive AgentsContraceptive UsageContraceptive methodsDevelopmentDevicesDoseEffectivenessEngineeringEnrollmentEnsureEstheticsEvaluation StudiesExcisionExerciseExogenous Hormone TherapyFederal GovernmentFeedbackFemaleFertilityFocus GroupsFormulationGoalsGroup MeetingsHandHormonalHormonesHospitalsHumanImmunoglobulin GInnovation CorpsInstitutional Review BoardsInterviewLeadLiteratureMeasuresMethodsMonoclonal AntibodiesMucous body substanceOutcomeParticipantPatient RecruitmentsPerceptionPersonsPharmacologyPregnancyProcessPropertyProviderReportingResearch DesignResearch PersonnelSafetySensorySheepSiteSperm MotilitySpermatozoa antibodyState GovernmentSurveysSystemTarget PopulationsThinkingUnited States National Institutes of HealthVaginaVaginal RingVaginal delivery procedureVariantWomanWorkbasecapsulecell motilitycomparativecostdemographicsdesigneggexperiencein vivoinsightmalephysical propertypreferencepreventproduct developmentprogramsprototypereproductive tractsatisfactionside effectsperm cellsuccesssynergismunintended pregnancyuptakewillingness
中文摘要
点击翻译按钮获取中文摘要
英文摘要
User-based identification of preferred design features for MM008, a non-hormonal contraceptive
vaginal ring
Project Summary
Nearly half of all pregnancies in the U.S. are unintended, and most occur in women who are not using
contraceptives. There are diverse reasons for not using contraceptives; one common reason is that many
women have a strong aversion to using exogenous hormones due to real and perceived side effects. It is likely
that contraceptive use and satisfaction would substantially increase if there was a non-hormonal, user-
controlled contraceptive method that did not require use immediately prior to intercourse, nor daily dosing. We
believe we can create such a non-hormonal contraceptive based on vaginal delivery of an anti-sperm
monoclonal antibody (mAb) that agglutinates and traps sperm in mucus, thereby preventing sperm from
reaching the egg. We have developed an exceptionally potent mAb, MM008, that target a well characterized
and validated antigen target universally present on all human sperm. MM008 is highly homogeneous and
stable, and can be produced at very high yields using conventional biomanufacturing processes. More
importantly, MM008 is >16-fold more potent than the best anti-sperm IgG known in the literature, aggulutinate
sperm even down to <100 ng/mL, and can reduce progressively motile sperm by 99.9% in the sheep vagina
within 2 mins at a dose of just 33 µg per sheep. We have since shown that we can steadily release MM008
from a proprietary capsule-intravaginal ring (IVR) system that sustains highly effective concentrations of
MM008 in the sheep vagina for over 20 days (more than adequate to cover the fertility window in most
women). These highly promising results motivated us to actively advance MM008-IVR into the clinic. Our goal
is to advance a product that suits the contraceptive needs for many women, with both high efficacy and high
user adoption. Thus, it is important for us to rigorously investigate user pereceptions and preferences that
could impact their willingness to try or use the product. In this proposal, we seek to respond to the RFA HD-22-
019 to identify preferred use characteristics (PUC) and investigate the user sensory perceptions and
experiences for MM008-IVR. In Specific Aim 1, we will conduct mixed method integrative design study to
examine the perceptibility and PUCs of non-hormonal contraception, including an in mano comparative
assessment of variants of our MM008-IVR. These user insights will be investigated initially through quantitative
online survey, and then followed by in-person focus groups. In Specific Aim 2, we will conduct a short-term
user experience study to evaluate the perceptibility and related PUC following vaginal insertion and use of a
non-medicated IVR identical in appearance and physical properties to the preferred MM008-IVR from Aim 1.
Successful completion of the proposed work will help ensure we are advancing a product that can meet the
contraceptive needs and preferences of millions of women in the U.S. and worldwide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis
-
批准号:10699458
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2023
-
负责人:Keiichiro Kushiro
-
依托单位:
Fast dissolving antibody tablets for preventing vaginal HSV transmission
-
批准号:10547476
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2022
-
负责人:Keiichiro Kushiro
-
依托单位:
Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody
-
批准号:10459074
-
项目类别:
-
资助金额:$27.77万
-
财政年份:2022
-
负责人:Keiichiro Kushiro
-
依托单位:
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV
-
批准号:9799170
-
项目类别:
-
资助金额:$91.1万
-
财政年份:2021
-
负责人:Keiichiro Kushiro
-
依托单位:
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV
-
批准号:10381449
-
项目类别:
-
资助金额:$79.11万
-
财政年份:2021
-
负责人:Keiichiro Kushiro
-
依托单位:
海外基金